23687-27-6

Basic information

• Product Name: 8-Aminoisoquinoline
• Synonyms: 8-AMINOISOQUINOLINE;ISOQUINOLIN-8-AMINE;ISOQUINOLIN-8-YLAMINE;8-Aminoisoquinoline95%;8-Aminoisoquinoline 98%;8-amine-isoquinoline;8-Isoquinolinamine;8-Aminoisoquinoline ,98%
• CAS NO: 23687-27-6
• Molecular Formula: C₉H₈N₂
• Molecular Weight: 144.17
• EINECS: -0
• Product Categories: Amines;blocks;Quinolines;Heterocyclic Series;Quinoline&Isoquinoline;Building Blocks;Isoquinoline
• Mol File: 23687-27-6.mol

Chemical Properties

• Melting Point: 155-157
• Boiling Point: 289.8 °C at 760 mmHg
• Flash Point: 171.5 °C
• Appearance: Brown/Crystalline Powder
• Density: 1.21 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.708
• Storage Temp.: Keep Cold
• PKA: 6.20±0.23(Predicted)
• CAS DataBase Reference: 8-Aminoisoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Aminoisoquinoline(23687-27-6)
• EPA Substance Registry System: 8-Aminoisoquinoline(23687-27-6)

Safety Data

• Hazard Codes: Xi
• Statements: 41
• Safety Statements: 26-39
• Hazardous Substances Data: 23687-27-6(Hazardous Substances Data)

Usage

Chemical Properties

Brown solid

InChI:InChI=1/C9H8N2/c10-9-3-1-2-7-4-5-11-6-8(7)9/h1-6H,10H2

Upstream product

• 3482-14-2 isoquinolin-8-ol 
• 1532-72-5 isoquinoline N-oxide 
• 119-65-3 isoquinoline 
• 65464-36-0 8-nitroisoquinoline-N-oxide 
• 58142-99-7 5-iodoisoquinoline 
• 1125-60-6 isoquinolin-5-ylamine 
• 34784-04-8 5-bromoisoquinoline 
• 63927-23-1 5-bromo-8-nitroisoquinoline 
• 401916-13-0 5-iodo-8-nitroisoquinoline 
• 7473-12-3 8-nitroisoquinoline 
• 58142-95-3 5-chloro-8-nitroisoquinoline 

Downstream Products

• 863290-48-6 2-benzoyl-8-chloro-1-cyano-1,2-dihydroisoquinoline 
• 863290-47-5 2-benzoyl-8-bromo-1-cyano-1,2-dihydroisoquinoline 
• 863290-55-5 8-bromo-1-(3,4-dimethoxy-benzyl)-isoquinoline 
• 863290-56-6 8-chloro-1-(3,4-dimethoxy-benzyl)-isoquinoline 
• 1131605-27-0 8-iodoisoquinoline 
• 1434081-75-0 C₄₂H₄₅N₅O₉S 
• 1348394-39-7 8-(3-biphenyl-4-yl-5-ethyl-4H-1,2,4-triazol-4-yl)isoquinoline 
• 369652-57-3 2-(8-isoquinolineamino)-3-nitrobenzoic acid 
• 63927-22-0 8-bromo-isoquinoline 

Relevant articles and documents

Copper(II) complex with oxazoline ligand: Synthesis, structures and catalytic activity for nitro compounds reduction

The Cu(II) complexes bearing bisoxazolines, tridentate pincer pybox and terpyridine ligands have been synthesized and fully characterized. The molecular structures of copper complexes 1a and 1c were confirmed by single-crystal X-ray diffraction methods. These copper complexes highly catalyzed nitro compounds reduction to aniline and its derivatives in the presence of NaBH4 reducing agent in water solvent. The complex 1e was an efficient catalyst toward nitro compounds reduction with wide functional group substrate scope and aliphatic nitro compounds.

6,6-Fused heterocyclic ureas as highly potent TRPV1 antagonists

A series of N-[{2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)-pyridin-3-yl}methyl] N′-(6,6-fused heterocyclic) ureas have been investigated as hTRPV1 antagonists. Among them, compound 15 showed highly potent TRPV1 antagonism to capsaicin, with Ki(ant) = 0.2 nM, as well as antagonism to other activators, and it was efficacious in a pain model. A docking study of 15 with our hTRPV1 homology model indicates that there is crucial hydrogen bonding between the ring nitrogen and the receptor, contributing to its potency.

PYRROLE ANTIFUNGAL AGENTS

The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof; wherein: R1, R2, R3, R4, R5, R6, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.

PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION

There is provided compounds of formula (I), wherein R1, R2, Ra and Rb have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.

Synthesis and radioligand binding studies of C-5- and C-8-substituted 1-(3,4-dimethoxybenzyl)-2,2-dimethyl-1,2,3,4-tetrahydroisoquinoliniums as SK channel blockers related to N-methyl-laudanosine and N-methyl-noscapine

The synthesis and the 125I-apamin binding studies of original C-5- and C-8-substituted 1-(3,4-dimethoxy-benzyl)-2,2-dimethyl-1,2,3,4- tetrahydroisoquinoliniums and 1-(3,4-dimethoxy-benzyl)-6,6-dimethyl-4,5,6,7- tetrahydrothieno[2,3-c]pyridiniums were performed in order to find a reversible and selective SK channel blocker structurally related to N-methyl-laudanosine and N-methyl-noscapine. A bulky alkyl substituent in the C-8 position of the tetrahydroisoquinoline produces a clear increase in the affinity for the apamin sensitive binding sites. The presence of an electron-withdrawing group in the C-5 and C-8 positions is not a suitable substitution for the affinity of drugs structurally related to N-methyl-laudanosine. Thiophenic analogues and 8-methoxy derivatives possess a poor affinity for the apamin sensitive binding sites. Electrophysiological studies performed with the most effective compound showed a blockade of the apamin sensitive afterhyperpolarization in rat dopaminergic neurons.

Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain; Structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaliue, and cinnoline moieties

Novel transient receptor potential vanilloid 1 (TRPV1) receptor antagonists with various bicyclic heteroaromatic pharmacophores were synthesized, and their in vitro activity in blocking capsaicin activation of TRPV1 was assessed. On the basis of the contribution of these pharmacophores to the in vitro potency, they were ranked in the order of 5-isoquinoline > 8-quinoline = 8-quinazoline > 8-isoquinoline ≥ cinnoline ≈ phthalazine ≈ quinoxaline ≈ 5-quinoline. The 5-isoquinoline-containing compound 14a (hTRPV1 IC50 = 4 nM) exhibited 46% oral bioavailability and in vivo activity in animal models of visceral and inflammatory pain. Pharmacokinetic and pharmacological properties of 14a are substantial improvements over the profile of the high-throughput screening hit 1 (hTRPV1 IC50 = 22 nM), which was not efficacious in animal pain models and was not orally bioavailable.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X1, X2, X3, X4, X5, R5, R6, R7, R8a, R8b, R9, Z1, Z2 and L are as defined in the description.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.